Victoria Stewart
Get their honest, personalized take on your startup.
Sign in to pitch Victoria →At a glance
- Full Name
- Victoria Stewart
- Title
- Senior Director of Investor Relations and Communications
- Firm
- Verona Pharma
- Firm Type
- Biopharmaceutical company; Verona Pharma became a subsidiary of Merck & Co., Inc. effective October 7, 2025
- Target Company Profile
- No public source verified Victoria Stewart as an active angel investor or venture check-writer; her verified roles are investor relations, communications, and public relations in life sciences
- Sector Focus
- Life sciences, biotechnology, biopharmaceuticals, respiratory diseases, investor relations and communications
- Geographic Focus
- UK / US life sciences communications and investor relations
- Location
- London, England, United Kingdom
Background
Victoria Stewart is a life-sciences communications and investor-relations professional, not a publicly verified angel investor. The latest primary-source role I found lists her as Senior Director of Investor Relations and Communications at Verona Pharma, where she served as the investor-relations contact on company announcements in 2024 and 2025.
Before Verona Pharma, Stewart worked at Abingworth, a transatlantic life-sciences investment firm. Abingworth’s own 2018 press release listed her as Director of Communications, with responsibility as a contact for the firm. Third-party profiles describe her as having joined Abingworth in 2000 from PJB Publications, where she was Biotechnology Editor of *Scrip World Pharmaceutical News*.
Her earlier background was in journalism and editorial roles covering pharmaceuticals, biotechnology, and medical devices. Public profiles say she held editorial positions at *Chemistry in Britain* and the *Financial Times*, and earned a degree in Biological Chemistry from the University of Kent at Canterbury. Her LinkedIn profile also verifies University of Kent and Verona Pharma.
Investment Thesis & Focus
- No public source verified a personal investment thesis, check size, or direct seed/angel investing activity for Victoria Stewart.
- Her Abingworth role was communications / public relations, not a named investing role. Abingworth described itself as an international life-sciences investment group investing across stages from startups to public companies.
- Abingworth’s firm-level investment appetite includes venture investments of $15 million to $30 million in total per company, primarily in the US and Europe, across biotherapeutics, small molecules, nucleic acid therapeutics, vaccines, gene therapies, cell therapies, specialty pharma, and platform technologies.
- Abingworth’s firm-level selection language emphasizes new treatments that “materially improve patients’ lives” and looks for “game-changers and paradigm-shifts, not just incremental improvements.”
- At Verona Pharma, Stewart’s work is investor communications for a respiratory biopharma company focused on chronic respiratory diseases and Ohtuvayre / ensifentrine.
Notable Investments
- No publicly verifiable personal angel investments, board-led venture deals, or portfolio companies were found for Victoria Stewart.
- Abingworth portfolio context only: Abingworth says it has invested in more than 200 life-science companies, with 75 IPOs and 53 M&A outcomes; these are firm-level results and are not personally attributed to Stewart.
- Verona Pharma: Stewart is listed as the IR / communications contact on Verona announcements; Verona agreed in July 2025 to be acquired by MSD / Merck for approximately $10 billion, with the transaction effective October 7, 2025. This is an investor-relations role, not a personal investment.
Unlock the full research
Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.
One-time. Stays unlocked for you.